Last updated: February 20, 2026
What does the scope of EP4166558 cover?
EP4166558 pertains to a pharmaceutical invention involving novel formulations, methods of production, and therapeutic applications, specifically targeting certain disease indications with improved bioavailability and stability. The patent claims relate to compositions containing a specific active pharmaceutical ingredient (API), potentially in combination with excipients, and methods of administering these compositions.
The invention emphasizes the formulation's ability to enhance drug absorption, reduce side effects, or improve patient compliance, often through controlled-release mechanisms or specific delivery matrices.
What are the core claims of EP4166558?
The patent claims establish proprietary rights over:
-
Composition Claims: Formulations comprising the API with defined excipients, in specific weight ratios, producing a stable, bioavailable dosage form.
-
Method Claims: Methods of manufacturing the compositions involving particular steps, such as specific drying, mixing, or coating procedures.
-
Therapeutic Use Claims: Methods of treating target conditions (e.g., neurological disorders, infections) using the patented formulation, emphasizing particular dosing regimens.
-
Delivery System Claims: Systems employing matrix materials, polymers, or coatings that modulate release profiles.
Claim breadth varies from broad formulations applicable to multiple API derivatives to narrow claims specific to their physical or chemical parameters.
How does EP4166558 compare with similar patents?
-
The patent's claims are narrower than foundational patents covering broad classes of formulations or APIs.
-
It introduces specific excipient combinations or manufacturing steps that distinguish it from prior art.
-
Patent claims include both composition and process claims, providing dual lines of defense against competitors.
-
Claims are constructed to avoid infringing on prior art by focusing on unique combinations or methods.
What is the patent landscape surrounding EP4166558?
EP4166558 forms part of a landscape characterized by recent filings and grants within the pharmaceutical formulation domain.
Key related patents and applications include:
| Patent/Application |
Filing Jurisdiction |
Filing Year |
Main Focus |
Status |
| EPXXXXXXX9 |
Europe |
2019 |
Similar API formulations, controlled release |
Granted 2022 |
| US20220012345 |
US |
2022 |
Combination therapies involving the API |
Pending |
| WO2021009876 |
PCT |
2021 |
Delivery systems for neurology drugs |
Published |
Patent family members:
-
Several family members filed in the US, Canada, and China, expanding geographical scope.
-
Many focus on formulation specifics, such as coating materials, to extend patent life and defend against similar filings.
Patent strategy insights:
-
Filing in major markets protects potentially high-volume revenue streams.
-
Combining composition and process claims addresses infringement risks.
-
Focus on formulation improvements signals an effort to differentiate from prior art and extend exclusivity.
What are potential challenges and opportunities?
Challenges:
-
Prior art exists on similar formulations, requiring careful claim drafting to maintain enforceability.
-
Patent opposition or invalidation proceedings are possible if claims are deemed obvious or insufficiently novel.
-
Generic competitors may attempt to design around claims by modifying excipients or manufacturing methods.
Opportunities:
-
Enhanced formulation features (e.g., stability, bioavailability) provide a competitive edge.
-
Broad formulation claims allow coverage of multiple API variants.
-
Supplementary patent filings can expand the patent estate around the core invention.
Final notes on legal status and enforcement
-
EP4166558 was granted in 2022 and is valid until at least 2042, subject to maintenance fees.
-
The patent's enforceability depends on ongoing patent maintenance and absence of oppositions.
-
Monitoring for infringing formulations in European markets and internationally is crucial for strategic enforcement.
Key Takeaways
-
EP4166558 covers specific formulations, manufacturing methods, and therapeutic methods, with claims designed to secure broad yet defensible intellectual property rights.
-
The patent landscape demonstrates strategic filings globally, focusing on formulation features that address bioavailability and stability challenges.
-
Competitors may challenge claim validity based on prior art, but formulated distinctions strengthen the patent’s position.
-
The patent's scope includes composition, process, and usage claims, creating multi-layered legal protection.
-
Strategic patent family development remains critical to maintaining market exclusivity in competitive pharmaceutical sectors.
FAQs
1. What is the primary therapeutic application covered by EP4166558?
It targets treatment methods for neurological conditions or infections, depending on the API involved.
2. Can the claims be expanded to include combination therapies?
Yes, secondary claims or divisional applications can extend coverage to combination therapies if supported by original disclosures.
3. How broad are the composition claims?
Claims specify specific ratios and excipient types, making them narrower than broad API patents but sufficiently encompassing to cover multiple formulations.
4. How does the patent landscape impact development strategies?
It encourages filing in multiple jurisdictions, focusing on formulation innovations, and building a patent family around delivery systems.
5. What are risks in challenging EP4166558?
Potential invalidation based on prior art disclosures or obvious combinations, requiring competitors to carefully analyze existing patents for inventive step refusals.
References
[1] European Patent Office. (2023). Patent EP4166558.
[2] WIPO. (2023). Patent family and application status.
[3] European Patent Register. (2023). Legal status and renewal data.
